DOCSLIB.ORG

FTY720-P) Nor SET Dimerization Or Ceramide Induction but Depends on Interaction with SET K209

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
FTY720-P) Nor SET Dimerization Or Ceramide Induction but Depends on Interaction with SET K209 Antagonistic activities of the immunomodulator and protein phosphatase 2A (PP2A)-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven myeloproliferative neoplasms. DISSERTATION Presented in Partial Fulfillment of the Requirements for the degree Doctor of Philosophy in the Graduate School of The Ohio State University By Joshua John Oaks, B.S. Integrated Biomedical Sciences Graduate Program The Ohio State University 2013 Dissertation Committee Danilo Perrotti MD, PhD Roger Briesewitz, PhD Denis Guttridge, PhD Harold Fisk, PhD Copyright 2013 Joshua John Oaks ABSTRACT FTY720 (Fingolimod, Gilenya) is a sphingosine analog used as an immunosuppressant in multiple sclerosis patients. FTY720 is also a potent protein phosphatase 2A (PP2A)- activating drug (PAD). PP2A is a tumor suppressor found inactivated in different types of cancer. We show here that PP2A is inactive in Polycythemia Vera (PV) and other myeloproliferative neoplasms (MPNs) characterized by the expression of the transforming Jak2V617F oncogene. PP2A inactivation occurs in a Jak2V617F dose/kinase- dependent manner through the PI-3Kγ-PKC-induced phosphorylation of the PP2A inhibitor SET and by modulation of nitric oxide synthase (NOS2)-induced nitrosylation of PP2A. Genetic and/or PAD-mediated PP2A reactivation induces Jak2V617F inactivation/downregulation and impairs clonogenic potential of Jak2V617F cell lines and PV but not normal CD34+ progenitors. Likewise, FTY720 decreases leukemic allelic burden, reduces splenomegaly and significantly increases survival of Jak2V617F leukemic mice without adverse effects. Mechanistically, we show that in Jak2V617F cells, FTY720 anti-leukemic activity neither requires FTY720 phosphorylation (FTY720-P) nor SET dimerization or ceramide induction but depends on interaction with SET K209. Moreover, we showed that Jak2V617F also utilizes an alternative sphingosine kinase-1 (SPHK1)- mediated pathway to inhibit PP2A, and that FTY720-P, acting as a sphingosine-1- phosphate-receptor-1 (S1PR1) agonist, elicits signals leading to the Jak2-PI-3Kγ-PKC- SET-mediated PP2A inhibition. Thus, PADs (e.g. FTY720) represent suitable therapeutic alternatives for Jak2V617F MPNs. ii ACKNOWLEDGEMENTS This work would not be possible without the help and guidance of many people to whom I am indebted. Firstly, I would like to thank my advisor, Dr. Danilo Perrotti. He has given me the inspiration, direction and opportunity to pursue the research I love. He is the spark that drives all of us who work for him and without his guidance and experience none of this work would be possible. Likewise, all of the current and former members of the Perrotti laboratory I have had the pleasure to work with have been essential making this work possible. I would also like to thank: Dr. J. Van Brocklyn who has served as my “sphingolipid expert” throughout this project. He was always willing to assist me with protocols, discussions, or experiments and was never reluctant to do so despite his busy schedule; Dr. Briesewitz for his technical support but more for his willingness to be involved with my professional development; and, finally, Drs. Landesman and Kalid, and Ms. Shechter, and the crew at Karyopharm for their enthusiasm for our research on pharmacologic development of SET inhibitors and their generosity allowing the continuation of this project. iii Vita et Studiorum Born March 18, 1977 . ………………………………………………………. Dayton, Ohio 2003 ………………………………………………B.S. Dietetics, University of Cincinnati Field of Study Major Field: Integrated Biomedical Sciences Area of Emphasis: Pharmacology iv Table of Contents Abstract…………………………………………………………………..……………..……ii Acknowledgements…………………………………………………………………..…….iii Vita et Studiorum…..………………………………………………………….……..……..iv List of Tables……………………………………………………………………………….vi List of Figures………………………………………………………………………….…..vii Chapters 1. Introduction……...………………………………………………….………………..1 2. Regulation of Jak2- and Jak2V617F-driven erythropoiesis…………...…......…..16 3. Methods…………………..…………………………………………………….…...92 4. Results………………………………………………………..………..……….….109 5. Discussion……………………………………………………………….………...139 6. Future Directions……………………………………………………………….....146 References………………………………………………………………………..…..……158 v List of Tables 1 List of major kinases regulated by PP2A…………………………….……..…42 2 S1P receptor G-protein coupling…………………………………………...….58 3 S1P1 downstream inhibitors……………………………………………...….…93 vi List of Figures 1 Jak2 and common Jak2 mutations ………………...……………………..…………4 2 Myeloid hematopoiesis …..………………………..………………..……...……..……13 3 Wild type and V617F Jak2 signaling ...…….………………..…………………...…14 4 Protein Phosphatase 2a (PP2A) ……………………….………..……………….........17 5 Nitric oxide synthase (NOS) activates PP2A …………………..……………..……….53 6 Sphingolipids ………………………………………………..…………….......…….57 7 FTY720 and FTY720-(S)-Phosphate …….……………………...………………..……84 8 FTY720 Immunosuppressive activity …...……………...…………….…………….85 9 FTY720 anti-cancer activity ………….....……………...…………….…………….89 10 Jak2V617F suppresses PP2A activity in a SET-dependent manner A and B……….110 10 Jak2V617F suppresses PP2A activity in a SET-dependent manner C and D………112 11 Jak2V617F/PI3Kγ/PKC signals inhibit PP2A through SET phosphorylation A.….…114 11 Jak2V617F/PI3Kγ/PKC signals inhibit PP2A through SET phosphorylation B.….…115 11 Jak2V617F/PI3Kγ/PKC signals inhibit PP2A through SET phosphorylation C and D…………………………………………………………………………………………...115 12 In vivo FTY720 anti-leukemic effects and lack of toxicity A and B ……………………………………………………………………………………….…….120 12 In vivo FTY720 anti-leukemic effects and lack of toxicity C…………………………121 12 In vivo FTY720 anti-leukemic effects and lack of toxicity D…………………………123 12 In vivo FTY720 anti-leukemic effects and lack of toxicity E…………………………124 13 FTY720 phosphorylation is dispensible for its anti-leukemic activity A….………125 13 FTY720 phosphorylation is dispensible for its anti-leukemic activity B….………126 vii 13 FTY720 phosphorylation is dispensible for its anti-leukemic activity C….………128 14 FTY720-P promotes Jak2 and suppresses PP2A activity A and B…..………....…131 14 FTY720-P promotes Jak2 and suppresses PP2A activity C…..………………....…132 14 FTY720-P promotes Jak2 and suppresses PP2A activity D and E…..………....…134 15 FTY720-dependent PP2A activation in myeloid cells depends on the SET K209- FTY720 interaction but not on SET dimerization or ceramide levels A and B...….136 15 FTY720-dependent PP2A activation in myeloid cells depends on the SET K209- FTY720 interaction but not on SET dimerization or ceramide levels C and D...….138 16 Antagonizing effect of FTY720 and FTY720-P on leukemogenesis……………….145 17 Novel FTY720 analogs …..…….………..............................................................…150 18 SET inhibitor development strategy……… ……………………..…….………..….…152 19 Molecular docking of FTY720 and SET………..………..……..………….……….…153 20 Novel SET inhibitors ……………………………….……………….......…………..…155 viii CHAPTER 1 INTRODUCTION Polycythemia Vera (PV) is a rare hematopoietic malignancy that involves the erythroid (red blood cell) system. It is currently defined as a myeloproliferative neoplasm (MPN) and affects fewer than 2 people in one million. This disorder was first described by Louis Vaquez in 1892 (1) and by William Osler in 1903 (2) and was originally called “Osler- Vaquez disease”. Initially, the disorder was associated to altitude sickness “the torpor, mental and physical; the sensation of fullness in the head, with headache, vertigo and in some cases nausea and vomiting, remind us of the symptoms to which mountain climbers and aeronauts are subject” (2). By modern definitions, PV typically manifests as uncontrolled erythropoiesis (3-5) with a hematocrit of >52% in Caucasian men and >47% in men of African origin or in women. Splenomegaly and pruritus are also common sympthoms used for diagnosis of PV (6). The high erythroid cell content in the peripheral blood (PB) of PV patients leads to hyperviscosity, which can result in thrombosis (7-12) and, therefore, in high risk for heart attack or stroke. While red blood cell count is still part of the PV diagnostic panel, a polymerase chain reaction (PCR)-based test is now used to assess presence of a mutated Janus Kinase 2 (Jak2) oncogene that in the majority of PV cases represents the hallmark of this hematologic disorder (see below). 1 1.1 The Jak2 receptor tyrosine kinase Janus Kinase 2 (Jak2) is a receptor-bound cytosolic tyrosine kinase consisting of 7 JH (Jak homology) domains: a Src homology 2 domain (SH2), a tyrosine kinase domain (JH1), two c-terminal domains, and a pseudokinase domain (JH2). The JH3-7 region forms a FERM (4.1 protein, ezrin, radixin, moesin-homology) domain, which is required for binding to the erythropoietin (EPO) receptor. Jak2 translates a conformational change caused by ligand [e.g. EPO] binding to cytokine receptors (e.g. EpoR) into an intracellular signaling cascade (13). This is accomplished by the phosphorylation of specific tyrosine residues on the receptor N-terminus (intracellular) that provides a docking site for signal transducer and activator of transcription (STAT) proteins (14, 15), which upon Jak2-dependent phosphorylation dimerize and relocate into the nucleus where they act as modulators of transcription (16-18). Chromosomal alterations and gene mutations have been reported for the Jak2 gene which results in a mutated Jak2 protein (Figure 1). The best described chromosomal abnormality is the gene translocation leading to the formation of chimeric tyrosine kinase protein TEL-Jak although a PCM1-Jak2
Load more

Recommended publications
  • Retinamide Increases Dihydroceramide and Synergizes with Dimethylsphingosine to Enhance Cancer Cell Killing
    2967 N-(4-Hydroxyphenyl)retinamide increases dihydroceramide and synergizes with dimethylsphingosine to enhance cancer cell killing Hongtao Wang,1 Barry J. Maurer,1 Yong-Yu Liu,2 elevations in dihydroceramides (N-acylsphinganines), Elaine Wang,3 Jeremy C. Allegood,3 Samuel Kelly,3 but not desaturated ceramides, and large increases in Holly Symolon,3 Ying Liu,3 Alfred H. Merrill, Jr.,3 complex dihydrosphingolipids (dihydrosphingomyelins, Vale´rie Gouaze´-Andersson,4 Jing Yuan Yu,4 monohexosyldihydroceramides), sphinganine, and sphin- Armando E. Giuliano,4 and Myles C. Cabot4 ganine 1-phosphate. To test the hypothesis that elevation of sphinganine participates in the cytotoxicity of 4-HPR, 1Childrens Hospital Los Angeles, Keck School of Medicine, cells were treated with the sphingosine kinase inhibitor University of Southern California, Los Angeles, California; D-erythro-N,N-dimethylsphingosine (DMS), with and 2 College of Pharmacy, University of Louisiana at Monroe, without 4-HPR. After 24 h, the 4-HPR/DMS combination Monroe, Louisiana; 3School of Biology and Petit Institute of Bioengineering and Bioscience, Georgia Institute of Technology, caused a 9-fold increase in sphinganine that was sustained Atlanta, Georgia; and 4Gonda (Goldschmied) Research through +48 hours, decreased sphinganine 1-phosphate, Laboratories at the John Wayne Cancer Institute, and increased cytotoxicity. Increased dihydrosphingolipids Saint John’s Health Center, Santa Monica, California and sphinganine were also found in HL-60 leukemia cells and HT-29 colon cancer cells treated with 4-HPR. The Abstract 4-HPR/DMS combination elicited increased apoptosis in all three cell lines. We propose that a mechanism of N Fenretinide [ -(4-hydroxyphenyl)retinamide (4-HPR)] is 4-HPR–induced cytotoxicity involves increases in dihy- cytotoxic in many cancer cell types.
    [Show full text]
  • Neurological S1P Signaling As an Emerging Mechanism of Action of Oral FTY720 (Fingolimod) in Multiple Sclerosis
    Arch Pharm Res Vol 33, No 10, 1567-1574, 2010 DOI 10.1007/s12272-010-1008-5 REVIEW Neurological S1P Signaling as an Emerging Mechanism of Action of Oral FTY720 (Fingolimod) in Multiple Sclerosis Chang Wook Lee1, Ji Woong Choi2, and Jerold Chun1 1Department of Molecular Biology, Dorris Neuroscience Center, The Scripps Research Institute, La Jolla, California 92037, USA and 2Department of Pharmacology, Division of Basic Medicine and Science, Gachon University of Medi- cine and Science, Incheon 406-799, Korea (Received August 15, 2010/Revised August 23, 2010/Accepted August 24, 2010) FTY720 (fingolimod, Novartis) is a promising investigational drug for relapsing forms of multi- ple sclerosis (MS), an autoimmune and neurodegenerative disorder of the central nervous sys- tem. It is currently under FDA review in the United States, and could represent the first approved oral treatment for MS. Extensive, ongoing clinical trials in Phase II/III have sup- ported both the efficacy and safety of FTY720. FTY720 itself is not bioactive, but when phospho- rylated (FTY720-P) by sphingosine kinase 2, it becomes active through modulation of 4 of the 5 known G protein-coupled sphingosine 1-phosphate (S1P) receptors. The mechanism of action (MOA) is thought to be immunological, where FTY720 alters lymphocyte trafficking via S1P1. However, MOA for FTY720 in MS may also involve a direct, neurological action within the cen- tral nervous system in view of documented S1P receptor-mediated signaling influences in the brain, and this review considers observations that support an emerging neurological MOA. Key words: FTY720, Fingolimod, Sphingosine 1-phosphate receptors, Multiple sclerosis, Cen- tral nervous system INTRODUCTION factors that initiate MS are still unknown.
    [Show full text]
  • Fingolimod (FTY720): Discovery and Development of an Oral Drug to Treat Multiple Sclerosis
    REVIEWS CASE HISTORY Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis Volker Brinkmann*, Andreas Billich*, Thomas Baumruker*, Peter Heining‡, Robert Schmouder§, Gordon Francis||, Shreeram Aradhye¶ and Pascale Burtin# Abstract | The discovery of fingolimod (FTY720/Gilenya; Novartis), an orally active immunomodulatory drug, has opened up new approaches to the treatment of multiple sclerosis, the most common inflammatory disorder of the central nervous system. Elucidation of the effects of fingolimod — mediated by the modulation of sphingosine 1‑phosphate (S1P) receptors — has indicated that its therapeutic activity could be due to regulation of the migration of selected lymphocyte subsets into the central nervous system and direct effects on neural cells, particularly astrocytes. An improved understanding of the biology of S1P receptors has also been gained. This article describes the discovery and development of fingolimod, which was approved by the US Food and Drug Administration in September 2010 as a first‑line treatment for relapsing forms of multiple sclerosis, thereby becoming the first oral disease‑modifying therapy to be approved for multiple sclerosis in the United States. Demyelination Multiple sclerosis (MS) is a chronic autoimmune disorder Treatment strategies for MS usually involve the man- Damage of the myelin sheath of the central nervous system (CNS) that is characterized agement of symptoms and the use of disease-modifying of axons. A demyelinating by inflammation leading to astrogliosis, demyelination, drugs to reduce the frequency of relapses and to slow disease is any disease of and loss of oligodendrocytes and neurons1. MS is the the progression of disability. Established first-line the nervous system in which the myelin sheath is damaged.
    [Show full text]
  • Targeting the Sphingosine Kinase/Sphingosine-1-Phosphate Signaling Axis in Drug Discovery for Cancer Therapy
    cancers Review Targeting the Sphingosine Kinase/Sphingosine-1-Phosphate Signaling Axis in Drug Discovery for Cancer Therapy Preeti Gupta 1, Aaliya Taiyab 1 , Afzal Hussain 2, Mohamed F. Alajmi 2, Asimul Islam 1 and Md. Imtaiyaz Hassan 1,* 1 Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, Jamia Nagar, New Delhi 110025, India; [email protected] (P.G.); [email protected] (A.T.); [email protected] (A.I.) 2 Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia; afi[email protected] (A.H.); [email protected] (M.F.A.) * Correspondence: [email protected] Simple Summary: Cancer is the prime cause of death globally. The altered stimulation of signaling pathways controlled by human kinases has often been observed in various human malignancies. The over-expression of SphK1 (a lipid kinase) and its metabolite S1P have been observed in various types of cancer and metabolic disorders, making it a potential therapeutic target. Here, we discuss the sphingolipid metabolism along with the critical enzymes involved in the pathway. The review provides comprehensive details of SphK isoforms, including their functional role, activation, and involvement in various human malignancies. An overview of different SphK inhibitors at different phases of clinical trials and can potentially be utilized as cancer therapeutics has also been reviewed. Citation: Gupta, P.; Taiyab, A.; Hussain, A.; Alajmi, M.F.; Islam, A.; Abstract: Sphingolipid metabolites have emerged as critical players in the regulation of various Hassan, M..I. Targeting the Sphingosine Kinase/Sphingosine- physiological processes. Ceramide and sphingosine induce cell growth arrest and apoptosis, whereas 1-Phosphate Signaling Axis in Drug sphingosine-1-phosphate (S1P) promotes cell proliferation and survival.
    [Show full text]
  • Gilenya; FTY720
    STRADER, CHERILYN R., M.S. Fingolimod (Gilenya; FTY720): A Recently Approved Multiple Sclerosis Drug Based on a Fungal Secondary Metabolite and the Creation of a Natural Products Pure Compound Database and Organized Storage System. (2012) Directed by Dr. Nicholas H. Oberlies, 78 pp. Fingolimod (Gilenya; FTY720), a synthetic compound based on the fungal secondary metabolite, myriocin (ISP-I), is a potent immunosuppressant that was approved in September 2010 by the U.S. FDA as a new treatment for multiple sclerosis (MS). Fingolimod was synthesized by the research group of Tetsuro Fujita at Kyoto University in 1992 while investigating structure-activity relationships of derivatives of the fungal metabolite, ISP-I, isolated from Isaria sinclairii. Fingolimod becomes active in vivo following phosphorylation by sphingosine kinase 2 to form fingolimod-phosphate, which binds to specific G protein-coupled receptors (GPCRs) and prevents the release of lymphocytes from lymphoid tissue. Fingolimod is orally active, which is unique among current first-line MS therapies, and it has the potential to be used in the treatment of organ transplants and cancer. The first chapter reviews the discovery and development of fingolimod, from an isolated lead natural product, through synthetic analogues, to an approved drug. Natural products play an important role in the pharmaceutical industry, accounting for approximately half of all drugs approved in the U.S. between 1981 and 2006. Given the importance of natural product research and the vast amount of data that is generated in the process, it is imperative that the pure compounds and data are stored in a manner that will allow researchers to derive as much value as possible.
    [Show full text]
  • The Development of Fingolimod (FTY720, Gilenya)
    Discovery Medicine ® www.discoverymedicine.com n ISSN: 1539-6509; eISSN: 1944-7930 A Mechanistically Novel, First Oral Therapy for Multiple Sclerosis: The Development of Fingolimod (FTY720, Gilenya) Jerold ChuN ANd Volker BrINkmANN Abstract: Multiple sclerosis (MS) is a chronic Introduction autoimmune disorder affecting the central nervous system (CNS) through demyelination and neurode - Multiple sclerosis (MS) is a neurological disorder char - generation. Until recently, major therapeutic treat - acterized by demyelination and neurodegeneration ments have relied on agents requiring injection within the central nervous system (CNS) with common delivery. In September 2010, fingolimod/FTY720 relapsing forms produced through autoimmune inflam - (Gilenya, Novartis) was approved by the FDA as the matory mechanisms (Compston and Coles, 2002) first oral treatment for relapsing forms of MS. involving autoreactive lymphocytes that penetrate the Fingolimod is a novel compound produced by chem - blood-brain barrier to attack the nervous system (Figure ical modification of a fungal precursor. Its active 1). MS is a major cause of nervous system disability metabolite, formed by in vivo phosphorylation, mod - affecting individuals in the prime of life with a 2-3:1 ulates sphingosine 1-phosphate (S1P) receptors that female to male ratio (Compston and Coles, 2002) and are a subset of a larger family of cell-surface, G pro - an estimated global prevalence of 2.5 million that is tein-coupled receptors (GPCRs) mediating the highest in Northern latitudes particularly amongst effects of bioactive lipids known as lysophospho - Caucasians (Noseworthy et al. , 2000; Rosati, 2001). lipids. Fingolimod’s mechanism of action in MS is The initiating causes of MS remain unknown not completely understood; however, its relevant (Baranzini et al.
    [Show full text]
  • Sphingolipids in Inflammation: from Bench to Bedside
    Mediators of Inflammation Sphingolipids in Inflammation: From Bench to Bedside Guest Editors: Kazuyuki Kitatani, Kazuhisa Iwabuchi, Ashley Snider, and Laura Riboni Sphingolipids in Inflammation: From Bench to Bedside Mediators of Inflammation Sphingolipids in Inflammation: From Bench to Bedside Guest Editors: Kazuyuki Kitatani, Kazuhisa Iwabuchi, Ashley Snider, and Laura Riboni Copyright © 2016 Hindawi Publishing Corporation. All rights reserved. This is a special issue published in “Mediators of Inflammation.” All articles are open access articles distributed under the Creative Com- mons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Editorial Board Anshu Agrawal, USA Christoph Garlichs, Germany Eeva Moilanen, Finland Muzamil Ahmad, India Mirella Giovarelli, Italy Jonas Mudter, Germany Simi Ali, UK Denis Girard, Canada Hannes Neuwirt, Austria Amedeo Amedei, Italy Ronald Gladue, USA Marja Ojaniemi, Finland Jagadeesh Bayry, France Hermann Gram, Switzerland Sandra Helena Penha Oliveira, Brazil Philip Bufler, Germany Oreste Gualillo, Spain Vera L. Petricevich, Mexico Elisabetta Buommino, Italy Elaine Hatanaka, Brazil Carolina T. Piñeiro, Spain Luca Cantarini, Italy Nina Ivanovska, Bulgaria Marc Pouliot, Canada Claudia Cocco, Italy Yona Keisari, Israel Michal A. Rahat, Israel Dianne Cooper, UK Alex Kleinjan, Netherlands Alexander Riad, Germany Jose Crispin, Mexico Magdalena Klink, Poland Sunit K. Singh, India Fulvio D’Acquisto, UK Marije I. Koenders, Netherlands HelenC.Steel,SouthAfrica Pham My-Chan Dang, France Elzbieta Kolaczkowska, Poland Dennis D. Taub, USA Wilco de Jager, Netherlands Dmitri V. Krysko, Belgium Kathy Triantafilou, UK Beatriz De las Heras, Spain Philipp M. Lepper, Germany Fumio Tsuji, Japan Chiara De Luca, Germany Changlin Li, USA Giuseppe Valacchi, Italy Clara Di Filippo, Italy Eduardo López-Collazo, Spain Luc Vallières, Canada Maziar Divangahi, Canada Antonio Macciò, Italy Elena Voronov, Israel Amos Douvdevani, Israel A.
    [Show full text]
  • The Sphingosine 1-Phosphate Signaling Pathway in Epilepsy: a Possible Role for The
    The sphingosine 1-phosphate signaling pathway in epilepsy: a possible role for the immunomodulator drug fingolimod in epilepsy treatment 1Antonio Leo, 1Rita Citraro, 2Rosario Marra, 1Ernesto Palma, 1Eugenio Donato Di Paola, 3Andrew Constanti, 1Giovambattista De Sarro, 1, *Emilio Russo. 1Science of Health Department, School of Medicine, University “Magna Graecia” of Catanzaro, Italy; 2National Council of Research (CNR), Institute of Neurological Science, Catanzaro, Italy; 3Department of Pharmacology, UCL School of Pharmacy, 29/39 Brunswick Square, London, United Kingdom. *Author for correspondence: Prof. Emilio Russo, Ph.D., Chair of Pharmacology, Department of Science of Health, School of Medicine, University of Catanzaro, Italy Via T. Campanella, 115 88100 Catanzaro, ITALY. Phone +39 0961 3694191; Fax +39 0961 3694192 e-mail: [email protected] 1 Abstract It is currently known that erythrocytes are the major source of sphingosine 1-phosphate (S1P) in the body. S1P acts both extracellularly as a cellular mediator and intracellularly as an important second messenger molecule. Its effects are mediated by interaction with five specific types of G protein-coupled S1P receptor. Fingolimod, is a recognized modulator of S1P receptors, and is the first orally active disease-modifying therapy that has been approved for the treatment of multiple sclerosis. Magnetic resonance imaging data suggest that fingolimod may be effective in multiple sclerosis by preventing blood-brain barrier disruption and brain atrophy. Fingolimod might also possess S1P receptor-independent effects and exerts both anti- inflammatory and neuroprotective effects. In the therapeutic management of epilepsy, there are a great number of antiepileptic drugs, but there is still a need for others that are more effective and safer.
    [Show full text]
  • Uptake of Exogenous Serine Is Important to Maintain Sphingolipid
    bioRxiv preprint doi: https://doi.org/10.1101/2020.03.30.016220; this version posted March 31, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 1 Uptake of exogenous serine is important to maintain sphingolipid 2 homeostasis in Saccharomyces cerevisiae 3 4 Bianca M. Esch1, Sergej Limar1, André Bogdanowski2,3, Christos Gournas4,#a, 5 Tushar More5, Celine Sundag1, Stefan Walter6, Jürgen J. Heinisch7, Christer S. 6 Ejsing5,8, Bruno André4 and Florian Fröhlich1,6* 7 8 1Department of Biology/Chemistry, Molecular Membrane Biology Group, University of 9 Osnabrück, Barbarastraße 13, 49076 Osnabrück, Germany 10 11 2Department of Biology/Chemistry, Ecology Group, University of Osnabrück, Barbarastraße 12 13, 49076 Osnabrück, Germany 13 14 3UFZ–Helmholtz Centre for Environmental Research Ltd, Department for Ecological 15 Modelling, Permoserstr. 15, 04318, Leipzig, Germany 16 17 4Molecular Physiology of the Cell, Université Libre de Bruxelles (ULB), Institut de Biologie et 18 de Médecine Moléculaires, 6041 Gosselies, Belgium 19 20 5Department of Biochemistry and Molecular Biology, Villum Center for Bioanalytical 21 Sciences, University of Southern Denmark, 5000 Odense, Denmark 22 23 6Center of Cellular Nanoanalytics Osnabrück, Barbarastraße 11, 49076 Osnabrück, 24 Germany 25 26 7Department of Biology/Chemistry, Division of Genetics, University of Osnabrück, 27 Barbarastraße 11, 49076 Osnabrück, Germany 28 29 8Cell Biology and Biophysics Unit, European Molecular Biology Laboratory, 69117 30 Heidelberg, Germany 31 32 33 *Corresponding author: 34 Email: [email protected] 35 Phone: +49-541-969-2961 36 37 38 #aCurrent address: 39 Microbial Molecular Genetics Laboratory 40 Institute of Biosciences and Applications (IBA) 41 National Centre for Scientific Research “Demokritos” (NCSRD) 42 Patr.
    [Show full text]
  • Regulation of the Activity of Mammalian Serine Palmitoyltransferase
    Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2016 Regulation of the activity of mammalian serine palmitoyltransferase Zhakupova, Assem Posted at the Zurich Open Repository and Archive, University of Zurich ZORA URL: https://doi.org/10.5167/uzh-129376 Dissertation Published Version Originally published at: Zhakupova, Assem. Regulation of the activity of mammalian serine palmitoyltransferase. 2016, Univer- sity of Zurich, Faculty of Science. Regulation of the Activity of Mammalian Serine Palmitoyltransferase ___________________________________________________________________________ Dissertation zur Erlangung der naturwissenschaftlichen Doktorwürde (Dr. sc. nat.) vorgelegt der Mathematisch-naturwissenschaftlichen Fakultät der Universität Zürich von Assem Zhakupova aus Kasachstan Promotionskomitee Prof. Dr. Arnold von Eckardstein (Vorsitz) Prof. Dr. Thorsten Hornemann Prof. Dr. Stephan Neuhauss PD Dr. Sabrina Sonda Dr. Ludovic Gillet Zürich, 2016 ii Table of contents Abstract............................................................................................................................................iv Zusammenfassung……………………………………………………………………………………………….vi General Introduction……………………………………………………………………………………………1 I. The sphingolipid metabolic pathway…………………………………………………………….1 II. The sphingolipid salvage pathway………………………………………………………………...5 III. Intracellular sphingolipid trafficking and transport……………………………………….7 IV. The mammalian SPT complex……………………………………………………………………….8
    [Show full text]
  • Effects of Inhibition of Serine Palmitoyltransferase (SPT) and Sphingosine Kinase 1 (Sphk1) on Palmitate Induced Insulin Resistance in L6 Myotubes
    Effects of Inhibition of Serine Palmitoyltransferase (SPT) and Sphingosine Kinase 1 (SphK1) on Palmitate Induced Insulin Resistance in L6 Myotubes Agnieszka Mikłosz*, Bartłomiej Łukaszuk, Marcin Baranowski, Jan Górski, Adrian Chabowski Department of Physiology, Medical University of Bialystok, Bialystok, Poland Abstract Background: The objective of this study was to examine the effects of short (2 h) and prolonged (18 h) inhibition of serine palmitoyltransferase (SPT) and sphingosine kinase 1 (SphK1) on palmitate (PA) induced insulin resistance in L6 myotubes. Methods: L6 myotubes were treated simultaneously with either PA and myriocin (SPT inhibitor) or PA and Ski II (SphK1inhibitor) for different time periods (2 h and 18 h). Insulin stimulated glucose uptake was measured using radioactive isotope. Expression of insulin signaling proteins was determined using Western blot analyses. Intracellular sphingolipids content [sphinganine (SFA), ceramide (CER), sphingosine (SFO), sphingosine-1- phosphate (S1P)] were estimated by HPLC. Results: Our results revealed that both short and prolonged time of inhibition of SPT by myriocin was sufficient to prevent ceramide accumulation and simultaneously reverse palmitate induced inhibition of insulin-stimulated glucose transport. In contrast, prolonged inhibition of SphK1 intensified the effect of PA on insulin-stimulated glucose uptake and attenuated further the activity of insulin signaling proteins (pGSK3β/GSK3β ratio) in L6 myotubes. These effects were related to the accumulation of sphingosine in palmitate treated myotubes. Conclusion: Myriocin is more effective in restoration of palmitate induced insulin resistance in L6 myocytes, despite of the time of SPT inhibition, comparing to SKII (a specific SphK1 inhibitor). Observed changes in insulin signaling proteins were related to the content of specific sphingolipids, namely to the reduction of ceramide.
    [Show full text]
  • Recent Insights Into the Interplay of Alpha-Synuclein and Sphingolipid Signaling in Parkinson’S Disease
    International Journal of Molecular Sciences Review Recent Insights into the Interplay of Alpha-Synuclein and Sphingolipid Signaling in Parkinson’s Disease Joanna A. Motyl 1 , Joanna B. Strosznajder 2 , Agnieszka Wencel 1 and Robert P. Strosznajder 3,* 1 Department of Hybrid Microbiosystems Engineering, Nalecz Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences, Ks. Trojdena 4 St., 02-109 Warsaw, Poland; [email protected] (J.A.M.); [email protected] (A.W.) 2 Department of Cellular Signalling, Mossakowski Medical Research Institute, Polish Academy of Sciences, 5 Pawinskiego St., 02-106 Warsaw, Poland; [email protected] 3 Laboratory of Preclinical Research and Environmental Agents, Mossakowski Medical Research Institute, Polish Academy of Sciences, 5 Pawinskiego St., 02-106 Warsaw, Poland * Correspondence: [email protected] Abstract: Molecular studies have provided increasing evidence that Parkinson’s disease (PD) is a protein conformational disease, where the spread of alpha-synuclein (ASN) pathology along the neuraxis correlates with clinical disease outcome. Pathogenic forms of ASN evoke oxidative stress (OS), neuroinflammation, and protein alterations in neighboring cells, thereby intensifying ASN toxicity, neurodegeneration, and neuronal death. A number of evidence suggest that homeostasis between bioactive sphingolipids with opposing function—e.g., sphingosine-1-phosphate (S1P) and ceramide—is essential in pro-survival signaling and cell defense against OS. In contrast, imbalance of the “sphingolipid biostat” favoring pro-oxidative/pro-apoptotic ceramide-mediated changes have been indicated in PD and other neurodegenerative disorders. Therefore, we focused on the role of sphingolipid alterations in ASN burden, as well as in a vast range of its neurotoxic effects.
    [Show full text]